Dasatinib

From Anvita Health Wiki

Contents 1 Introduction 2 Indications 3 Dosage 4 Pharmacokinetics 5 Adverse-effects 6 Drug-interactions 7 Mechanism-of-action 8 More General Terms 9 Internet Database 10 References

Introduction

• Tradename: Sprycel

Indications

• chronic myeloid leukemia ( CML)
• Philadelphia chromosome + acute lymphoblastic leukemia ( ALL)
• for patient not responding to other therapies

Dosage

• usual dose is 70 mg PO BID

• Tabs: 20, 50, 70 mg

Pharmacokinetics

• metabolized by CYP3A4

Adverse-effects

• bleeding
• diarrhea
• skin rash
• infections
• headache
• fatigue
• edema
• nausea
• anemia
• neutropenia
• thrombocytopenia
• abnormal liver function tests
• pulmonary hypertension (rare) [3]

Drug-interactions

• levels may be increased by drugs that inhibit cyt P450 3A4

• St John's wort

• levels may be decreased by drugs that induce cyt P450 3A4
• proton pump inhibitors may decrease absorption of dasatinib

Mechanism-of-action

• inhibits proliferation of abnormal leukocytes
• said to act similarl to imatinib ( Gleevec)
• may inhibit bcl- abl Bristol-Myers Squibb Cost $5000/month 2006

More General Terms

• antineoplastic agent (chemotherapeutic agent)
• protein kinase inhibitor

Internet Database

PubChem: 3062316

References

1. Prescriber's Letter 13(8): 2006 FDA Approves Sprycel, a New Treatment for a Rare Type of Leukemia Detail-Document#: [1] (subscription needed) [2]
2. Cortes JE et al Results of dasatinib therapy in patients with early chronic- phase chronic myeloid leukemia. J Clin Oncol 2010 Jan 20; 28:398. PMID: [3]
3. FDA MedWatch: 10/11/2011 Sprycel (dasatinib): Drug Safety Communication - Risk of Pulmonary Arterial Hypertension [4]

dasatinib (Sprycel)